Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  DRG Market Assessment Reports

Biomarker-Driven Prescribing in Oncology: Physician and Payer Insights on Evolving Trends in Key Indications | Physician & Payer Forum | US | 2014

Login to access report north_east
Contact sales account_box

Oncology is increasingly moving toward a personalized treatment approach, enlisting predictive biomarkers to guide therapy choice. This trend is already being felt in indications as varied as breast cancer, colorectal cancer, and malignant melanoma, and is affecting uptake of key brands. In addition, multiple emerging therapies in the oncology pipeline, such as Novartis’s Zykadia (ceritinib) and Amgen’s rilotumumab, hope to benefit from biomarker-driven prescribing.

Predictive biomarkers give oncologists more confidence that a patient will respond to a therapy. Biomarker testing also means that payers do not have to reimburse therapies that will not work in biomarker-negative patients, allowing funds to be allocated more efficiently. However, problems can arise in obtaining sufficient high-quality tissue from a biopsy in order to perform biomarker testing, and delays in receiving results of biomarker tests can adversely affect prescribing of biomarker-driven therapies. Furthermore, how biomarker tests are reimbursed will in turn impact uptake of biomarker-driven therapies.

Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Hepatitis B Virus – Geographic Focus: China – China In-Depth – Hepatitis B Virus
HBV is a major public health burden in China, with chronically infected individuals at a significantly increased risk of developing hepatic cirrhosis and hepatocellular carcinoma. Current treatment…
north_east
Report
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Current Treatment – Current Treatment: Physician Insights – B-Cell Non-Hodgkin’s Lymphoma (US)
Non-Hodgkin’s lymphoma (NHL) represents a diverse group of hematological malignancies broadly classified into indolent and aggressive subtypes. Patients with aggressive NHL—diffuse large B-cell…
north_east
Report
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Current Treatment – Treatment Sequencing – B-Cell Non-Hodgkin’s Lymphoma (US)
Key benefits and usesPinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.Drill down into physicians’ treatment sequences and understand who to position against…
north_east
Report
Psoriasis – Unmet Need – Unmet Need – Moderate to Severe Psoriasis (US/EU)
Topical therapies are the backbone of psoriasis management; however, they are often inadequate for patients with moderate to severe disease, who typically require systemic treatment. While…
north_east
Report
Non-Small-Cell Lung Cancer – Unmet Need – Unmet Need – Metastatic NSCLC without driver mutations (US EU)
First-line treatment for non-small-cell lung cancer (NSCLC) patients without driver mutations typically includes an immune checkpoint inhibitor, with or without platinum-based chemotherapy,…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east